Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible antibody (AvidiMab and GlyMab) and two therapeutic vaccine platforms (Moditope and ImmunoBody) with the potential to treat various cancers.

Investment Perspective

Scancell is a clinical stage biotechnology company focused on the adaptive immune system, with four distinct technology platforms: two promising oncology vaccine platforms (Moditope and ImmunoBody), and two antibody technologies (GlyMab and AvidiMab). These have the potential to treat many solid cancers, either as monotherapy or in combination with other agents. Modi-1, the first Moditope programme, is progressing in a Phase I/II trial targeting hard-to-treat solid tumours, and further efficacy data, notably in combination regimens, are due during 2024. The lead ImmunoBody programme, currently SCIB1, has already demonstrated impressive response data in the ongoing Phase II study in metastatic melanoma, with a transition to the next-generation iSCIB1+ expected in coming months. The broad acting GlyMab antibodies are generating exciting preclinical data; a first partnering deal with antibody expert Genmab was executed in October 2022, and further deals are possible. AvidiMab technology could be increasingly employed to enhance avidity and potency. Our risk adjusted NPV valuation for Scancell is £304m, or 33p per share, with significant upside from multiple upcoming catalysts.

Market information

SymbolPrimary exchanges


Heading into important 2024 clinical catalysts
Update | 31 Jan 2024
Successful upsized placing raises over £10m
Lighthouse | 01 Dec 2023
Business update and FY23 results
Lighthouse | 31 Oct 2023

Recent News

Scancell to present at AACR 2024
02 Apr 2024
First iSCIB1+ patient dosed
26 Mar 2024
Appointment of Sath Nirmalananthan to the Board of Directors
14 Mar 2024
Next-Gen Immuno-Oncology conference presentation
04 Mar 2024